Ajovy and Injection site cellulitis - a phase IV clinical study of FDA data

Summary:

Injection site cellulitis is reported as a side effect among people who take Ajovy (fremanezumab-vfrm), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Depakene, and have Migraine.

The phase IV clinical study analyzes which people have Injection site cellulitis when taking Ajovy. It is created by eHealthMe based on reports of 8,788 people who have side effects when taking Ajovy from the FDA, and is updated regularly.

What is Ajovy?

Ajovy has active ingredients of fremanezumab-vfrm. eHealthMe is studying from 8,834 Ajovy users. Check the latest studies of Ajovy.

What is Injection site cellulitis?

Injection site cellulitis (injection site inflammation) is found to be associated with 167 drugs and 307 conditions by eHealthMe. Check the latest studies of Injection site cellulitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

8,788 people reported to have side effects when taking Ajovy.
Among them, 13 people (0.15%) have Injection site cellulitis.

Could Ajovy cause Injection site cellulitis?

Among these 13 people:

How long have people been on Ajovy when they have Injection site cellulitis? *

What is the gender of people who have Injection site cellulitis when taking Ajovy? *

female: 100 %
male: 0.0 %

What is the age of people who have Injection site cellulitis when taking Ajovy? *

What are other drugs people take besides Ajovy? *

Sumatriptan Succinate: 3 people, 23.08%
Depakene: 3 people, 23.08%
Ubrelvy: 1 person, 7.69%
Naproxen Sodium: 1 person, 7.69%
Aimovig: 1 person, 7.69%

What are other side effects people have besides Injection site cellulitis? *

Injection Site Erythema (redness at injection site): 5 people, 38.46%
Injection Site Mass: 3 people, 23.08%
Injection Site Swelling: 2 people, 15.38%
Injection Site Irritation: 2 people, 15.38%
Migraine (headache): 1 person, 7.69%
Injection Site Warmth: 1 person, 7.69%
Injection Site Vesicles (fluid- or air-filled cavity or sac at injection site): 1 person, 7.69%
Injection Site Scar: 1 person, 7.69%
Injection Site Rash: 1 person, 7.69%
Injection Site Pruritus (severe itching at injection site): 1 person, 7.69%

What are the existing conditions these people have? *

Migraine (headache): 8 people, 61.54%

* Approximation only. Some reports may have incomplete information.

Do you take Ajovy and have Injection site cellulitis?

- Check whether Injection site cellulitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ajovy:

Ajovy (8,834 reports)

Browse all side effects of Ajovy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site cellulitis:

Injection site cellulitis (167 drugs)

Browse all the conditions that are associated with Injection site cellulitis:

Injection site cellulitis (307 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fremanezumab-vfrm (the active ingredients of Ajovy) and Ajovy (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.